Market Closed -
Australian S.E.
10:32:13 21/07/2023 am IST
|
5-day change
|
1st Jan Change
|
0.003
AUD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
50.66
|
25.33
|
27.14
|
10.49
|
14.07
|
1.479
|
Enterprise Value (EV)
1 |
46.73
|
23.33
|
27.57
|
8.029
|
14.24
|
1.521
|
P/E ratio
|
-29.7
x
|
-14.8
x
|
-7.31
x
|
-1.22
x
|
-1.7
x
|
-0.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
24.8
x
|
9.23
x
|
18.3
x
|
8.72
x
|
5.34
x
|
0.98
x
|
EV / Revenue
|
22.9
x
|
8.5
x
|
18.6
x
|
6.67
x
|
5.4
x
|
1.01
x
|
EV / EBITDA
|
-29.1
x
|
-14.6
x
|
-8.05
x
|
-1.35
x
|
-1.81
x
|
-0.23
x
|
EV / FCF
|
-55.7
x
|
-18.2
x
|
-35.4
x
|
-2.54
x
|
-2.67
x
|
-3.48
x
|
FCF Yield
|
-1.8%
|
-5.49%
|
-2.82%
|
-39.4%
|
-37.4%
|
-28.7%
|
Price to Book
|
11.9
x
|
9.95
x
|
-22.3
x
|
4.54
x
|
22.7
x
|
-0.86
x
|
Nbr of stocks (in thousands)
|
90,473
|
90,473
|
90,473
|
2,09,820
|
2,70,560
|
4,92,944
|
Reference price
2 |
0.5600
|
0.2800
|
0.3000
|
0.0500
|
0.0520
|
0.003000
|
Announcement Date
|
14/09/18
|
27/09/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/02/24
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.04
|
2.745
|
1.484
|
1.203
|
2.635
|
1.508
|
EBITDA
1 |
-1.606
|
-1.597
|
-3.425
|
-5.958
|
-7.852
|
-6.479
|
EBIT
1 |
-1.703
|
-1.67
|
-3.499
|
-5.99
|
-7.872
|
-6.5
|
Operating Margin
|
-83.47%
|
-60.83%
|
-235.72%
|
-497.78%
|
-298.75%
|
-431.08%
|
Earnings before Tax (EBT)
1 |
-1.699
|
-1.71
|
-3.713
|
-6.397
|
-7.303
|
-6.355
|
Net income
1 |
-1.699
|
-1.71
|
-3.713
|
-6.397
|
-7.303
|
-6.355
|
Net margin
|
-83.27%
|
-62.3%
|
-250.17%
|
-531.62%
|
-277.14%
|
-421.46%
|
EPS
2 |
-0.0189
|
-0.0189
|
-0.0410
|
-0.0410
|
-0.0306
|
-0.0171
|
Free Cash Flow
1 |
-0.8393
|
-1.28
|
-0.7779
|
-3.163
|
-5.329
|
-0.4371
|
FCF margin
|
-41.14%
|
-46.65%
|
-52.41%
|
-262.85%
|
-202.22%
|
-28.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/09/18
|
27/09/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/02/24
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
0.43
|
-
|
0.17
|
0.04
|
Net Cash position
1 |
3.94
|
2
|
-
|
2.46
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1263
x
|
-
|
-0.022
x
|
-0.006468
x
|
Free Cash Flow
1 |
-0.84
|
-1.28
|
-0.78
|
-3.16
|
-5.33
|
-0.44
|
ROE (net income / shareholders' equity)
|
-34.1%
|
-50.3%
|
-560%
|
-1,174%
|
-499%
|
1,165%
|
ROA (Net income/ Total Assets)
|
-19.3%
|
-26.3%
|
-101%
|
-163%
|
-164%
|
-133%
|
Assets
1 |
8.789
|
6.508
|
3.675
|
3.916
|
4.462
|
4.776
|
Book Value Per Share
2 |
0.0500
|
0.0300
|
-0.0100
|
0.0100
|
0
|
-0
|
Cash Flow per Share
2 |
0.0500
|
0.0200
|
0.0100
|
0.0100
|
0
|
0
|
Capex
1 |
0.04
|
0.02
|
-
|
0.06
|
0.03
|
0.11
|
Capex / Sales
|
1.95%
|
0.78%
|
-
|
5.38%
|
1.23%
|
7.07%
|
Announcement Date
|
14/09/18
|
27/09/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 988K | | +29.77% | 49.46B | | +1.00% | 42.58B | | +50.47% | 42.49B | | -5.26% | 29.09B | | +13.68% | 26.61B | | -22.99% | 18.64B | | +8.22% | 13.16B | | +32.41% | 12.55B | | -1.62% | 11.98B |
Other Biotechnology & Medical Research
|